Get the Stockscreener App
72.87
1.96%
-1.46
After Hours:
72.00
-0.87
-1.19%
Corcept Therapeutics Inc stock is traded at $72.87, with a volume of 664.12K.
It is down -1.96% in the last 24 hours and down -0.98% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
See More
Previous Close:
$74.33
Open:
$74.28
24h Volume:
664.12K
Relative Volume:
0.66
Market Cap:
$7.68B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
57.83
EPS:
1.26
Net Cash Flow:
$142.60M
1W Performance:
+5.06%
1M Performance:
-0.98%
6M Performance:
+32.49%
1Y Performance:
+104.06%
1-Day Range:
$71.61
$74.79
1-Week Range:
$67.32
$74.79
52-Week Range:
$35.87
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
72.87 | 7.55B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Scientech Research LLC Sells 4,716 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
AQR Capital Management LLC Sells 23,561 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Analysts Set Corcept Therapeutics Incorporated (NASDAQ:CORT) Price Target at $134.50 - MarketBeat
FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer - sharewise.com
Bayforest Capital Ltd Acquires 5,739 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Empowered Funds LLC Has $13.97 Million Stock Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept’s (CORT) Multibagger Momentum Builds on Relacorilant and Expanding Commercial Footprint - Insider Monkey
FDA Accepts NDA for Relacorilant in Platinum-Resistant Ovarian Cancer - Targeted Oncology
Central serous chorioretinopathy Pipeline Analysis & Clinical - openPR.com
Central serous chorioretinopathy Pipeline Analysis & Clinical Trials, 2025, DelveInsight | Targeted Therapy Technologies, Corcept Therapeutics, Bayer, and others - Barchart.com
Jacobs Levy Equity Management Inc. Decreases Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
Coppell Advisory Solutions LLC Purchases 14,590 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept's ovarian cancer treatment under FDA review (CORT) - Seeking Alpha
Corcept Therapeutics Says FDA Accepts NDA on Relacorilant for Treating Ovarian Cancer - MarketScreener
Fda reviews Corcept's nda for relacorilant in drug-resistant ovarian cancer - MarketScreener
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire
Checkpoint Capital L.P. Acquires Shares of 5,000 Corcept Therapeutics Incorporated $CORT - MarketBeat
Published on: 2025-09-08 19:18:57 - beatles.ru
Predicting Corcept Therapeutics Incorporated trend using moving averages2025 Price Momentum & Fast Exit Strategy with Risk Control - Newser
Canaccord Genuity Maintains a Buy on Corcept Therapeutics (CORT), Retains a $137 PT - MSN
Is Corcept Therapeutics Incorporated a good ESG investmentJuly 2025 Action & Entry Point Confirmation Alerts - خودرو بانک
Published on: 2025-09-06 00:29:23 - خودرو بانک
Ieq Capital LLC Buys 7,844 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Can Corcept Therapeutics Incorporated weather a recession2025 Trade Ideas & Free Safe Capital Growth Stock Tips - خودرو بانک
Corcept Therapeutics Incorporated stock retracement – recovery analysisQuarterly Profit Report & AI Forecasted Entry and Exit Points - Newser
predicting corcept therapeutics incorporated trend using moving averagesJuly 2025 Weekly Recap & Real-Time Chart Pattern Alerts - Newser
Can Corcept Therapeutics Incorporated hit a new high this monthJuly 2025 Short Interest & Safe Capital Allocation Plans - Newser
Is it time to cut losses on Corcept Therapeutics IncorporatedInsider Buying & Safe Capital Allocation Plans - Newser
Key resistance and support levels for Corcept Therapeutics IncorporatedDollar Strength & Reliable Intraday Trade Alerts - Newser
Assessing Insider Selling at Corcept Therapeutics: Strategic and Market Implications - AInvest
Corcept therapeutics CEO Belanoff sells $2.8m in shares By Investing.com - Investing.com Canada
Corcept Therapeutics officer Maduck sells $1.4m in shares By Investing.com - Investing.com South Africa
Corcept therapeutics exec Guyer sells $1.4m in shares By Investing.com - Investing.com Canada
Corcept Therapeutics officer Maduck sells $1.4m in shares - Investing.com
Lyon of Corcept Therapeutics sells $351k in shares By Investing.com - Investing.com Canada
Corcept therapeutics exec Guyer sells $1.4m in shares - Investing.com India
Corcept therapeutics CEO Belanoff sells $2.8m in shares - Investing.com
Corcept Therapeutics Incorporated stock momentum explainedMarket Growth Summary & High Accuracy Trade Signal Alerts - Newser
Price momentum metrics for Corcept Therapeutics Incorporated explainedQuarterly Earnings Summary & Reliable Price Breakout Signals - Newser
259,650 Shares in Corcept Therapeutics Incorporated $CORT Purchased by Driehaus Capital Management LLC - MarketBeat
How to track smart money flows in Corcept Therapeutics IncorporatedJuly 2025 Opening Moves & High Conviction Buy Zone Alerts - Newser
Pattern recognition hints at Corcept Therapeutics Incorporated upside2025 Volume Leaders & AI Driven Stock Movement Reports - Newser
Can momentum traders help lift Corcept Therapeutics IncorporatedPortfolio Update Report & Safe Capital Investment Plans - Newser
Published on: 2025-09-03 06:08:46 - Newser
Applying sector rotation models to Corcept Therapeutics Incorporated2025 Market WrapUp & High Accuracy Trade Signal Alerts - Newser
Will Corcept Therapeutics Incorporated benefit from geopolitical trendsQuarterly Market Summary & Long-Term Growth Plans - خودرو بانک
Published on: 2025-09-03 11:50:42 - خودرو بانک
Quantitative breakdown of Corcept Therapeutics Incorporated recent moveDay Trade & Stepwise Swing Trade Plans - Newser
What are the future prospects of Corcept Therapeutics IncorporatedJuly 2025 Summary & Safe Capital Growth Trade Ideas - خودرو بانک
Why is Corcept Therapeutics Incorporated stock going up2025 Price Momentum & Low Drawdown Trading Strategies - خودرو بانک
What are Corcept Therapeutics Incorporated’s earnings expectationsBull Run & Weekly Return Optimization Plans - خودرو بانک
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):